{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:54:22Z","timestamp":1794480862491,"version":"4.9.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018957","name":"Cara","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021204","name":"California State Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021204","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jid.2025.04.035","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:16:45Z","timestamp":1747826205000},"page":"175-183.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Systemic Inflammatory Markers Correlate with Chronic Kidney Disease\u2013Associated Pruritus and Response to Treatment"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6435-9707","authenticated-orcid":false,"given":"Robert H.","family":"Spencer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9176-5902","authenticated-orcid":false,"given":"Stephen A.","family":"Kilfeather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7153-9607","authenticated-orcid":false,"given":"Elaine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7862-8576","authenticated-orcid":false,"given":"Catherine","family":"Munera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2128-3832","authenticated-orcid":false,"given":"Warren","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-7453","authenticated-orcid":false,"given":"Shayan","family":"Shirazian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-7161","authenticated-orcid":false,"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3584-1665","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9rique","family":"Menzaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.04.035_bib1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000368940","article-title":"Update on inflammation in chronic kidney disease","volume":"39","author":"Akchurin","year":"2015","journal-title":"Blood Purif"},{"key":"10.1016\/j.jid.2025.04.035_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0165-5728(95)00159-X","article-title":"Inhibition of primary murine macrophage cytokine production in vitro following treatment with the kappa-opioid agonist U50,488H","volume":"64","author":"Alicea","year":"1996","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jid.2025.04.035_bib3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: a new key player in dermatology and beyond","volume":"141","author":"Ba\u011fci","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2025.04.035_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2025.04.035_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2025.04.035_bib7","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/hdi.12521","article-title":"Symptoms among patients receiving in-center hemodialysis: a qualitative study","volume":"21","author":"Cox","year":"2017","journal-title":"Hemodial Int"},{"key":"10.1016\/j.jid.2025.04.035_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1610-0387.2005.05706.x","article-title":"Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus","volume":"3","author":"Dugas-Breit","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jid.2025.04.035_bib9","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.3389\/fimmu.2019.02904","article-title":"The role of opioid receptors in immune system function","volume":"10","author":"Eisenstein","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2025.04.035_bib11","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1093\/ndt\/gfr053","article-title":"Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications","volume":"26","author":"Fallahzadeh","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jid.2025.04.035_bib12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2025.04.035_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2025.04.035_bib14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ekir.2020.01.006","article-title":"Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients","volume":"5","author":"Fishbane","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jid.2025.04.035_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100513","article-title":"Safety and tolerability of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis from the Phase 3 clinical trial program","volume":"4","author":"Fishbane","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.jid.2025.04.035_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/brbi.1994.1021","article-title":"Both T cells and macrophages are targets of kappa-opioid-induced immunosuppression","volume":"8","author":"Guan","year":"1994","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jid.2025.04.035_bib17","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jaci.2023.06.023","article-title":"Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis","volume":"152","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2025.04.035_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2340\/00015555-2280","article-title":"Clinical findings and provision of care in haemodialysis patients with chronic itch: new results from the German epidemiological haemodialysis itch study","volume":"96","author":"Hayani","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2025.04.035_bib19","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1586\/ern.10.154","article-title":"Nerve growth factor, pain, itch and inflammation: lessons from congenital insensitivity to pain with anhidrosis","volume":"10","author":"Indo","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.jid.2025.04.035_bib20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ndt\/gfi204","article-title":"The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients","volume":"21","author":"Kimmel","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jid.2025.04.035_bib21","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jaad.2014.08.004","article-title":"Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis","volume":"71","author":"Ko","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.04.035_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000341268","article-title":"Efficacy and safety of a novel \u0138-agonist for managing intractable pruritus in dialysis patients","volume":"36","author":"Kumagai","year":"2012","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jid.2025.04.035_bib23","first-page":"327","article-title":"Dermal mast cell density and pruritus in end-stage renal failure","volume":"23","author":"Leong","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.jid.2025.04.035_bib24","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2215\/CJN.00100110","article-title":"A longitudinal study of uremic pruritus in hemodialysis patients","volume":"5","author":"Mathur","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jid.2025.04.035_bib25","first-page":"285","article-title":"Pruritus and mast cell proliferation of the skin in end stage renal failure","volume":"23","author":"Matsumoto","year":"1985","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jid.2025.04.035_bib26","first-page":"136","article-title":"Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells","volume":"34","author":"Mettang","year":"1990","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jid.2025.04.035_bib27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ki.2013.454","article-title":"Uremic pruritus","volume":"87","author":"Mettang","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.jid.2025.04.035_bib28","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/sj.ki.5000251","article-title":"Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients","volume":"69","author":"Narita","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jid.2025.04.035_bib29","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1093\/ndt\/gfl461","article-title":"Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"21","author":"Pisoni","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jid.2025.04.035_bib30","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S1567-5769(01)00128-X","article-title":"Administration of mu-, kappa- or delta2-receptor agonists via osmotic minipumps suppresses murine splenic antibody responses","volume":"1","author":"Rahim","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jid.2025.04.035_bib31","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2025.04.035_bib32","doi-asserted-by":"crossref","first-page":"i23","DOI":"10.1093\/ckj\/sfab200","article-title":"Unravelling the pathophysiology of chronic kidney disease-associated pruritus","volume":"14","author":"Schricker","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jid.2025.04.035_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/IJNRD.S108045","article-title":"Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges","volume":"10","author":"Shirazian","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.jid.2025.04.035_bib34","series-title":"PW251: anti-inflammatory effects of the peripheral kappa Opioid receptor agonist CR845: a novel approach for the treatment of inflammatory disease","author":"Spencer","year":"2010"},{"key":"10.1016\/j.jid.2025.04.035_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12882-024-03790-w","article-title":"Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa Opioid receptor agonist for the treatment of pruritus","volume":"25","author":"Spencer","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jid.2025.04.035_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/toxins14030197","article-title":"The serum level of IL-31 in patients with chronic kidney disease-associated pruritus: what can we expect?","volume":"14","author":"\u015awierczy\u0144ska","year":"2022","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.jid.2025.04.035_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175214","article-title":"The role of kappa opioid receptors in immune system - an overview","volume":"933","author":"Szczepaniak","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jid.2025.04.035_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.745658","article-title":"Pruritus: a sensory symptom generated in cutaneous immuno-neuronal crosstalk","volume":"13","author":"Sz\u00f6ll\u0151si","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jid.2025.04.035_bib39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1073\/pnas.88.2.360","article-title":"Immunomodulatory activity of mu- and kappa-selective opioid agonists","volume":"88","author":"Taub","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2025.04.035_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100512","article-title":"Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 Phase 3 studies","volume":"4","author":"Topf","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.jid.2025.04.035_bib42","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ekir.2020.04.027","article-title":"CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management","volume":"5","author":"Verduzco","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jid.2025.04.035_bib43","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaad.2020.06.991","article-title":"Clinically meaningful change in itch intensity scores: an evaluation in patients with chronic kidney disease-associated pruritus","volume":"84","author":"Vernon","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.04.035_bib44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s41687-021-00404-z","article-title":"Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus","volume":"5","author":"Vernon","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jid.2025.04.035_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2025.04.035_bib46","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1681\/ASN.2005020152","article-title":"Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies","volume":"16","author":"Wikstr\u00f6m","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jid.2025.04.035_bib47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jid.2025.04.035_bib48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrneph.2017.52","article-title":"The systemic nature of CKD","volume":"13","author":"Zoccali","year":"2017","journal-title":"Nat Rev Nephrol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25004920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25004920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:37:40Z","timestamp":1774859860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25004920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0022202X25004920"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.04.035","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Inflammatory Markers Correlate with Chronic Kidney Disease\u2013Associated Pruritus and Response to Treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.04.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}